Home/Pipeline/ZMC-002

ZMC-002

BCMA-positive multiple myeloma

Phase 1Active

Key Facts

Indication
BCMA-positive multiple myeloma
Phase
Phase 1
Status
Active
Company

About Zhongmou Therapeutics

Clinical-stage biotech developing next-generation engineered T cell therapies for hematological cancers and solid tumors.

View full company profile

Therapeutic Areas